BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD
27.74
+0.31 (+1.13%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close27.43
Open27.50
Bid27.74 x 800
Ask27.75 x 1400
Day's Range27.23 - 28.01
52 Week Range18.72 - 31.97
Volume3,621,051
Avg. Volume3,366,945
Market Cap9.778B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 09, 2010
1y Target Est34.59
  • Financial Times

    Pina Bausch’s brutal, problematic Bluebeard finally gets its Sadler’s Wells debut

    Doors and windows line the perimeter as if setting the stage for farce, but there are few laughs in store. While Listening to a Tape Recording of Bela Bartok’s Opera “Duke Bluebeard’s Castle”, was first performed in Wuppertal in 1977 but had its belated UK premiere at Sadler’s Wells on Wednesday. The musical lèse majesté and the relentless brutality of the movement unnerved many in the original audience (walkouts were commonplace), and eventually so irritated the Bartok estate that they pulled the performance rights in 1994.

  • Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
    Zacks

    Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?

    Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • MarketWatch

    Bausch Health to reduce debt by $100 million using cash from operations

    Bausch Health Cos. iNc. said Wednesday it is reducing debt by $100 million using cash from operations. The drug company, formerly called Valeant, has been working to reduce the debt burden accumulated during the Valeant years, which is still more than $23 billion, according to FactSet data. The company will redeem $100 million of its outstanding 5.50% senior notes that mature in March of 2023. Shares were not yet active premarket but have gained 11% in the last 12 months, while the S&P 500 has gained 22%.

  • PR Newswire

    Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations.

  • Recent Panic Creates Long-Term Opportunity in China’s Luckin Coffee
    InvestorPlace

    Recent Panic Creates Long-Term Opportunity in China’s Luckin Coffee

    Only two questions really matter for Luckin Coffee (NASDAQ:LK). Can Luckin outgrow Starbucks (NASDAQ:SBUX) in China? If so, what is LK stock worth in that bullish scenario? Everything else is just noise.Source: Keitma / Shutterstock.com Luckin has dealt with a lot of noise of late. The spread of the coronavirus in China has led to store closures which will dent the company's sales and profits for at least the first quarter of 2020. A short-seller report drove panic selling as well.But investors shouldn't focus on short-term issues at the expense of the long-term trend. The trend promises potentially enormous returns for Luckin Coffee shareholders. All those issues have done is create a more attractive entry point.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Luckin Coffee Soars -- And TumblesJust a few weeks ago, LK stock was one of the market's best performers. Thanks in part to a blowout third-quarter earnings report in November, shares rose almost 200% in a little over two months.Two developments ended the rally. Coronavirus fears rattled global stocks, and took LK down with them. * 7 Utility Stocks to Buy That Offer Juicy Dividends To add to the panic, Muddy Waters Research, via Twitter (NYSE:TWTR), linked to an anonymous report alleging that Luckin had fraudulently inflated its numbers. The 89-page report claimed to rest on video of 620 Luckin stores across China. Those tests suggested that the number of items sold per day was overstated by 69% in the third quarter of 2019. The report alleged pricing inflation as well.LK stock plunged over 10% that day, capping a 35% decline in just nine trading sessions. Short-Term FearsThe problem with the selloff is that neither issue changes the long-term case for Luckin.Luckin is going toe-to-toe with Starbucks in the world's most populated country -- and winning. Luckin now has more stores in the country than does Starbucks. It's growing faster than its U.S. rival. And its model of often-unmanned stores and app-focused checkout procedures both suggest operating profit margins at maturity should be quite attractive.The long-term opportunity here is why investors bid Luckin up so sharply after the third-quarter report. Early results show that Luckin is succeeding in shifting Chinese customers away from tea to coffee -- and keeping those customers away from Starbucks. The company has plans to add thousands more stores to attract hundreds of millions more customers. And thanks to a convertible bond and stock offering last month, it has the capital to do so.Neither piece of short-term news impacts that long-term bull case. The spread of the coronavirus will be contained at some point. The short-seller report looks questionable.In fact, Citron Research, well-known for shorting the likes of Shopify (NYSE:SHOP) and Bausch Health (NYSE:BHC), has said it is long LK stock. The report "will fall short on accuracy," Citron wrote last week. The firm added that it expected Luckin's management to respond.Management did respond this week, and flatly denied the report. Investors listened. Luckin stock soared 15.6% in trading on Tuesday. The Long-Term Case for LK StockThat rally should continue as the short-term fears fade. From a long-term standpoint, LK stock still looks reasonably cheap.Admittedly, the company isn't profitable. But that's no surprise. Upfront spending to acquire new customers and to build out new stores is leading to near-term losses. But there's a clear path for Luckin to grow into a nicely profitable business. As long as that path continues, LK stock can rise as have so many other growth stocks in this market.Looking at revenue, the stock already doesn't appear that expensive. Luckin stock trades for a little over 5x Wall Street's estimate for 2020 sales. SBUX trades for roughly 4x revenue. Surely, investors should pay a modest premium for a substantially greater growth opportunity. Starbucks' core markets in the U.S. and Europe are largely saturated. Luckin has no such problem in China.As long as Luckin's opportunity remains intact, and the company executes, LK stock can keep gaining. The noise that drove recent volatility is meaningless in that context. Some investors took the selloff as a buying opportunity on Tuesday. I expect more will do so going forward.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post Recent Panic Creates Long-Term Opportunity in China's Luckin Coffee appeared first on InvestorPlace.

  • PR Newswire

    Bausch Health Announces Participation In Upcoming Investor Conferences

    Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in three investor conferences.

  • CNW Group

    Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month

    BRIDGEWATER, N.J. , and CHICAGO , Feb. 3, 2020 /CNW/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), and Prevent Blindness, the nation's oldest volunteer eye health non-profit organization, today announced they are collaborating throughout the month of February for the fifth consecutive year to raise awareness of Age-Related Macular Degeneration (AMD), one of the leading causes of vision loss in adults 50 years of age and older. "Each year, we look forward to joining forces with Bausch + Lomb to help bring awareness to this pervasive and potentially sight-stealing condition," said Jeff Todd , president and CEO, Prevent Blindness. Throughout February, Bausch + Lomb and Prevent Blindness will post a variety of content on their social media pages to share facts and helpful information about AMD with the public.

  • PR Newswire

    Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), and Prevent Blindness, the nation's oldest volunteer eye health non-profit organization, today announced they are collaborating throughout the month of February for the fifth consecutive year to raise awareness of Age-Related Macular Degeneration (AMD), one of the leading causes of vision loss in adults 50 years of age and older.

  • CNW Group

    Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program

    LAVAL, Quebec , Feb. 3, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a $10,000 scholarship in support of their academic goals.

  • MarketWatch

    Bausch Health, Clearside Biomedical publish data on eye drug

    Shares of Bausch Health Companies Inc. were up 0.3% in premarket trading on Tuesday after it announced the publication of late-stage trial data for an investigational eye therapy it is developing with Clearside Biomedical Inc. . Clearside's stock was up 9%. The experimental therapy, Xipere, is being tested as a treatment for macular edema associated with uveitis. The Phase 3 study, called the Peachtree Study, showed that about half of the patients taking the treatment had an improvement in visual acuity. Bausch's stock is up 17% over the last 52 weeks, while shares of Clearside have gained 161%. The Health Care Sector Sector SPDR Fund , an exchange-traded fund, has climbed about 14%.

  • PR Newswire

    Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the randomized, controlled, double-masked Phase 3 clinical trial (PEACHTREE study) of XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension), an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.1

  • Barrons.com

    Disney Stock Looks Attractive for the Next 10 Years, Bill Priest Says

    Barron’s Roundtable panelist William Priest says that by focusing on creative talent and shared infrastructure, Disney can make a meaningful transition.

  • Should Value Investors Pick Bausch Health (BHC) Stock Now?
    Zacks

    Should Value Investors Pick Bausch Health (BHC) Stock Now?

    Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.

  • CNW Group

    Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19

    Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19

  • PR Newswire

    Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference

    Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") has published a brief company update presentation designed to complement remarks that will be provided by management during a fireside chat at 1:30 p.m. PT (4:30 p.m. ET) today during the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company's recent performance and achievements, including updates on the Company's 2019 commitments and development programs, and offers insight into future goals and catalysts for 2020 and beyond.

  • PR Newswire

    Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)

    Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology (JDD) published positive results from two large Phase 3, multicenter, double-blind, placebo-controlled clinical trials (Studies 1 and 2) demonstrating the efficacy, safety and tolerability of ARAZLOTM (tazarotene) Lotion, 0.045%, the first FDA approved tazarotene in lotion form for patients with moderate to severe acne.1 A post hoc analysis of male patients in the two Phase 3 studies was also published by JDD.2 The U.S. Food and Drug Administration (FDA) approved ARAZLO for the topical treatment of acne vulgaris in patients nine years of age and older in December 2019.

  • GuruFocus.com

    What We Can Learn From Bill Ackman's Turnaround

    The activist guru's recovery is a lesson for everyone Continue reading...

  • Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
    PR Newswire

    Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced the U.S. launch of expanded parameters for Biotrue® ONEday for Astigmatism daily disposable contact lenses. The expansion will increase the toric parameter range by more than 60 percent, offering eye care professionals and their astigmatic patients the largest parameter offering of any daily disposable toric lens.1

  • CNW Group

    Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference

    Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference